glp 1 agonists adverse effects of GLP-1 class drugs. Gastrointestinal issues are Glucagon-like Receptor-1 agonists for obesity:

However, given the associated risks of cardiovascular disease and various cancers, the benefits of these medications, such as better glycemic control, weight loss and improvement in cardiometabolic risk factors as well as other obesity complications, appear to outweigh the risks for most adults with obesity [143, 153]

In this study, 422 participants who lost over 5% of initial body weight on a low-calorie diet were randomized to liraglutide 3.0 mg or placebo for 56 weeks

However, the cost of these medications and coverage exclusion by many payors in the US results in access challenges for many patients that could benefit

The findings identified Comp68, Comp70, and Comp71 as promising DPP4is with high selectivity scores and favorable MD total energies

(US), Amgen Inc